Germline mutations in the RET tyrosine kinase gene are responsible for the development of multiple endocrine neoplasia 2A and 2B (MEN2A and MEN2B). However, knowledge of the fundamental principles that determine the mutant RET-mediated signaling remains elusive. Here, we report increased expression of mitogen-activated protein kinase phosphatase-2 (MKP-2) in carcinomas developed in transgenic mice carrying RET with the MEN2A mutation (RET-MEN2A). The expression of MKP-2 was not only induced by RET-MEN2A or RET-MEN2B mutant proteins but also by the activation of endogenous RET by its ligand, glial cell line-derived neurotrophic factor (GDNF). MKP-2 expression was also evident in the MKK-f cell line, which was established from a mammary tumor developed in a RET-MEN2A transgenic mouse. Inhibition of MKP-2 attenuated the in vitro and in vivo proliferation of MKK-f cells, which was mediated by the suppression of cyclin B1 expression. Furthermore, we found that MKP-2 is highly expressed in medullary thyroid carcinomas derived from MEN2A patients. These findings suggest that the increased expression of MKP-2 may play a crucial role in oncogenic signaling downstream of mutant RET, leading to deregulation of cell cycle.
Introduction
The RET proto-oncogene encodes a receptor tyrosine kinase that acts as a functional receptor for the glial cell line-derived neurotrophic factor (GDNF) family of ligands (GFLs). It has a crucial role in transducing growth and differentiation signals in tissues derived from the neural crest and the developing kidney (Schuchardt et al., 1994; Moore et al., 1996; Pichel et al., 1996; Sa´nchez et al., 1996; Treanor et al., 1996; Rosenthal, 1999; Airaksinen and Saarma, 2002) . It has been firmly established that germline mutations in the RET gene are responsible for several forms of human diseases. RET loss-of-function mutations predispose for enteric neural crest cell dysfunction, which leads to Hirschsprung's disease, whereas its gainof-function mutations are found in several human cancers, including multiple endocrine neoplasia (MEN) type 2A (MEN2A) and 2B (MEN2B), familial medullary thyroid carcinoma (FMTC) and papillary thyroid carcinoma (Donis-Keller et al., 1993; Mulligan et al., 1993; Carlson et al., 1994; Edery et al., 1994; Hofstra et al., 1994; Romeo et al., 1994) . The MEN2A mutations were identified primarily in cysteine residues of the RET extracellular domain that lead to ligandindependent RET dimerization via the formation of an intermolecular disulfide bond (Asai et al., 1995; Santoro et al., 1995; Eng, 1999) . The MEN2B mutations, characterized by a methionine-to-threonine change at codon 918 or an alanine-to-phenylalanine change at codon 883 in the tyrosine kinase domain, result in an increase of intrinsic RET catalytic activity (Carlson et al., 1994; Gimm et al., 1997; Smith et al., 1997) .
Of particular interest are marked differences in affected organs and disease phenotype among individuals and kindreds with MEN2A, MEN2B or FMTC mutations (Kodama et al., 2005; Asai et al., 2006) . MEN2A is characterized by MTC, pheochromocytoma and parathyroid adenoma, whereas MEN2B shows a more complex phenotype, with association of MTC, pheochromocytoma, mucosal neuroma, intestinal ganglioneuromatosis and skeletal deformity. FMTC patients develop MTC only. The diversity and complexity of the phenotypes observed with MEN2A, MEN2B and FMTC patients suggest that the mutant RET protein is responsible for distinct patterns of intracellular signaling cascades.
Previous studies have revealed that constitutive phosphorylation of tyrosine residues in the intracellular domains of RET-MEN2A and RET-MEN2B mutant proteins results in activation of the Ras/Raf/mitogenactivated protein kinase (MAPK), phosphatidylinositol-3 kinase/Akt, p38 MAPK and c-Jun amino-terminal kinase (JNK) pathways (Takahashi, 2001; Airaksinen and Saarma, 2002; Kodama et al., 2005; Asai et al., 2006) . Because all of these pathways are also activated by the GFLs via endogenous RET, the question arises as to how the signals downstream of the RET mutants are distinct from those promoted by normal RET, in which the duration and strength of signals are tightly regulated.
To elucidate the developmental mechanisms of the MEN2A phenotype, we established transgenic mice expressing RET-MEN2A that developed salivary, thyroid and mammary gland carcinomas (Kawai et al., 2000) . In this study, cDNA microarrays were used to analyse global gene expression patterns in salivary, thyroid and mammary carcinomas to identify potential molecular determinants of RET-MEN2A-dependent tumorigenesis.
MAPK phosphatase-2 (MKP-2; DUSP4), one of the genes that was upregulated in all the carcinomas was chosen for further study. MKP-2 was first identified as a dual-specificity phosphatase that selectively dephosphorylates the p42/44 MAPK, p38 MAPK and JNK (Guan and Butch, 1995; Misra-Press et al., 1995; Farooq and Zhou, 2004; Cadalbert et al., 2005; Dickinson and Keyse, 2006; Owens and Keyse, 2007) . Interestingly, despite the activity of MKP-2 in inhibiting the activity of the MAPKs, depletion of MKP-2 by RNA interference resulted in deregulation of the cell cycle and proliferative inhibition of MKK-f, a cell line that was established from a mammary carcinoma developed in a RET-MEN2A transgenic mouse (Kawai et al., 2003) . We also found that the expression of MKP-2 was induced downstream of GDNF activation of normal RET in a temporally regulated manner that may orchestrate the tempo and duration of MAPK activation in a physiological context. These data suggest that constitutively induced expression and activity of MKP-2 may be necessary to maintain continuous proliferation of RET-MEN2A-driven carcinomas and present a previously unrecognized role for MKP-2.
Results
Analysis of gene expression in carcinomas from RET-MEN2A transgenic mice We previously reported the establishment of RET-MEN2A transgenic mice, which express a recombinant human RET-MEN2A gene (Cys634-Arg) driven by Moloney murine leukemia virus long terminal repeat (MoMuLV LTR) (Kawai et al., 2000) . At 6 months of age, all transgenic mice developed MTC and approximately one-half of the mice developed salivary gland or mammary gland adenocarcinomas (Kawai et al., 2000) .
To define the genes that are potentially involved in tumorigenesis in RET-MEN2A transgenic mice, we compared gene expression between pooled carcinomas and normal tissues from six independent mice using cDNA microarrays (Table 1) . The expression levels of 11 genes were upregulated more than twofold (log ratio) in all of the carcinoma tissues (thyroid, salivary and mammary carcinomas). Validation of the microarray results with quantitative reverse transcription (RT)-PCR showed that 7 of the 11 genes showed similar trends or much higher expression levels when compared with the microarray data. These seven genes were mouse Ret, Col11a1, Cxcl1, Usp18, Slc35d3, MKP-2 and Tde2l (Table 1) .
Induction of MKP-2 expression by RET-MEN2A, RET-MEN2B or normal RET activation MKP-2 (also termed DUSP4), a dual-specificity phosphatase that possesses phosphatase activity toward MAPKs (p42/44 MAPK, p38 MAPK and JNK) (Farooq and Zhou, 2004; Dickinson and Keyse, 2006; Owens and Keyse, 2007) was chosen for further study. The expression levels of the MKP-2 protein were examined by immunostaining sections from the mammary and salivary carcinomas and normal tissues from RET-MEN2A transgenic mice (Figure 1a) . Consistent with the microarray analysis, MKP-2 expression was not detected in the ductal epithelial cells of the normal mammary and salivary glands but was highly expressed in the mammary and salivary carcinomas. MKP-2 immunoreactivity was detected predominantly in the cytoplasm and weakly in the nucleus.
We next examined whether the expression of MKP-2 is induced by the overexpression of mutant RET protein. MKP-2 transcript and protein expression were significantly upregulated in NIH3T3 cells that stably expressed RET-MEN2A or RET-MEN2B (Figures 1b  and c) . MEF3T3 lines that express RET-MEN2A and RET-MEN2B under the control of a tetracyclinesuppressible (Tet-off) promoter were also used to examine the effect of mutant RET on MKP-2 expression. At 2 days after the induction of RET, the levels of MKP-2 mRNA and protein were analysed by semiquantitative RT-PCR and western blot analysis, respectively. As shown in Figures 1d and e, MKP-2 mRNA and protein were induced over a time course similar to that of RET induction. The expression of MKP-2 was also apparent in the MKK-f cell line, which was established from mammary carcinoma from a RET-MEN2A transgenic mouse (Kawai et al., 2003) (Figures  1b and c) . These results indicate that mutant RET is capable of inducing MKP-2 expression.
To investigate whether MKP-2 expression is induced by the activation of endogenous RET by GDNF, TGW neuroblastoma cells, which have been shown to express both endogenous RET and GFRa1 (Watanabe et al., 2002; Uchida et al., 2006) , were treated with GDNF. MKP-2 was weakly expressed in TGW cells in their basal state, and biphasic induction of MKP-2 was observed 15 min and 6 h after GDNF stimulation Figure S1) . The biphasic induction of MKP-2 was transient, thus it is conceivable, in physiological contexts, that the temporally regulated expression of MKP-2 may orchestrate the duration and strength of the MAPK activation in endogenous RET activation. Though the first phase of MKP-2 upregulation was correlated with consequent dephosphorylation of p42/44 MAPK, its second phase, which reached a maximum at 6 h after GDNF stimulation, did not apparently correlated with the re-activation and dephosphorylation of p42/44 MAPK. The data may hint at more complicated function of MKP-2 that is not limited to the inhibition of MAPKs activation.
MKP-2 exhibits phosphatase activity toward p42/44 and p38 MAPKs, but not JNK, in MKK-f cells Although previous studies have shown that MKP-2, when activated by p42/44 MAPK, possesses the activity to dephosphorylate p42/44 and p38 MAPKs, and JNK, its substrate specificity remains controversial (Farooq and Zhou, 2004; Cadalbert et al., 2005; Dickinson and Keyse, 2006; Owens and Keyse, 2007) . To confirm the phosphatase activity of MKP-2, HEK293 cells were transfected with mouse wild-type MKP-2 and its catalytically inactive mutant (MKP-2 C280S), in which the cysteine at residue 280 in the catalytic domain was mutated to serine (Cadalbert et al., 2005) . Epidermal growth factor (EGF)-mediated phosphorylation of p42/ 44 MAPK was attenuated by exogenous expression of wild-type MKP-2 and enhanced by the C280S mutant ( Figure 2a) . No difference was observed in the activation of p38 MAPK and JNK between wild-type MKP-2 and CS mutant-transfected HEK293 cells (data not shown).
The effect of RET-MEN2A-induced MKP-2 expression on the activity of MAPKs was further examined by the small-interfering RNA (siRNA)-mediated transient depletion (knock down) of MKP-2 in MKK-f cells. The activation of p42/44 and p38 MAPKs was modestly augmented by the depletion of MKP-2 in MKK-f cells (Figure 2b ). In contrast, there was little effect on the activation of JNK, suggesting that MKP-2 possesses phosphatase activity toward p42/44 and p38 MAPKs in MKK-f cells. These findings, in conjunction with those from the HEK293 cells, suggest that the effects of phosphatase activity of MKP-2 on MAPKs differ depending on the cell line used. On the whole, the effect of MKP-2 depletion on the dephosphorylation of the MAPKs was not remarkable, which may be accounted for by the fact that other members of MKPs, especially MKP-3 (DUSP6) and MKP-4 (DUSP9), were upregulated in MKP-2-depleted MKK-f cells (Supplementary Figure S2) .
Depletion of MKP-2 inhibits the proliferation of MKK-f cells in vitro and in vivo We next investigated the effect of MKP-2 on the proliferation of RET-MEN2A-driven cancer cells. Two lines of MKK-f cells were established in which MKP-2 was depleted by stable expression of short-hairpin RNA Immunostaining analyses also revealed that MKP-2 knockdown causes an accumulation of mitotic cells, especially at prophase and prometaphase, in which the chromosomes start to condense and separation of the centriole pairs was completed, respectively (Supplementary Figure S3) . The molecular mechanism of the G2/M blockade mediated by the depletion of MKP-2 was examined via expression of cell cycle regulators, including those implicated in the G2/M transition (Figure 5b ). The depletion of MKP-2 in MKK-f cells resulted in up to eightfold suppression of cyclin B1 expression, a regulatory subunit of M-phase-promoting factor that has a crucial role in the G2/M checkpoint (Norbury and Nurse, 1992; Pines, 1999; Takizawa and Morgan, 2000; Porter and Donoghue, 2003) . In contrast, we did not observe any effects on the expression of other cyclins and cyclin-dependent kinases (CDKs) that were examined. The downregulation of cyclin B1 expression was mediated by both shRNA and siRNA-mediated depletion of MKP-2 (Figures 5b and c) , demonstrating that the downregulation of cyclin B1 is not attributed to 'offtarget' effects of RNAi. The downregulation of cyclin B1 in MKP-2-depleted cells was mediated by transcriptional inhibition rather than protein degradation (Figure 5d ).
Cyclin B1 is the cyclin that binds to and activates cdc2 kinase (also termed CDK1) (Takizawa and Morgan, 2000; Porter and Donoghue, 2003) . As predicted, in the MKP-2-depleted MKK-f cells, downregulation of cyclin B1 resulted in a decrease in cdc2 kinase activity in both asynchronized and synchronized MKK-f cells (Figures  5b and e) . Thus, the inhibition of cell proliferation by MKP-2 depletion appears to be associated with downregulation of cyclin B1, which results in the inhibition of cdc2 kinase activity and cell cycle delay in the G2/M transition. The downregulation of cyclin B1 was also confirmed by immunocytochemistry, in which the appearance of cyclin B1 on the spindle poles at prometaphase was decreased in MKP-2-depleted MKK-f cells compared with control cells (Figure 5f ). It seems that MKP-2 exerts its regulatory effects during the cell cycle independent of the de-phosphorylating activity of MAPKs, because forced activation of p42/44 MAPK or p38 MAPK did not lead to the downregulation of cyclin B1 (Supplementary Figures  S4a and b) .
Expression of MKP-2 and cyclin B1 in MEN2A-associated MTCs Finally, to test whether the expression of MKP-2 is induced in human hereditary cancers driven by RET mutations, the expression of MKP-2 was examined in human MTC specimens. MKP-2 was highly expressed in MTC tumor cells, from five MEN2A patients, in which Roles of MKP-2 in RET-MEN2A-induced tumorigenesis T Hasegawa et al the overexpression of cyclin B1 was also demonstrated (Figure 6a ). Immunofluorescent studies showed that MKP-2 is apparently expressed in the cytoplasm, with weak expression in the nucleus, of tumor cells that were positive for calcitonin, an MTC marker (Figure 6b ). Weak MKP-2 expression was also detected in parafollicular C cells in MEN2A patients (Figure 6c ), whereas it was very low or undetectable in normal thyroid follicular and parafollicular cells (Figures 6b-e) .
Discussion
Germline or somatic RET mutations lead to various forms of human diseases. Its gain-of-function mutations are responsible for MEN2A, MEN2B and FMTC, as well as sporadic MTC and papillary thyroid carcinoma. Despite much investigation, it is still unknown how signaling downstream of the oncogenic RET is distinct from that mediated by normal RET activation The present study was designed to gain insights into the mechanisms underlying the action of mutant RET protein. DNA microarray analysis was used to identify differentially expressed genes relevant for tumor development in RET-MEN2A transgenic mice. We found that the expression of MKP-2 is significantly induced in RET-MEN2A-driven carcinoma cells and plays an important role in their proliferation both in vitro and in vivo. MKP-2 is a dual-specificity phosphatase known to inactivate MAPKs (Farooq and Zhou, 2004; Cadalbert et al., 2005; Dickinson and Keyse, 2006; Owens and Keyse, 2007) , as was confirmed by the present study (Figure 2) . However, despite an important function of MKP-2 in regulating the activity of MAPKs, evidence is limited for its role in tumor progression. In contrast to what was speculated, RNAi-mediated stable depletion of MKP-2 resulted in a decrease in the proliferation of MKK-f cells, suggesting a possible role of MKP-2 in potentiating tumorigenesis. The underlying mechanisms for this finding are currently unknown. Because continuous overactivation of Ras/Raf/MAPK signaling in some contexts can result in senescence, cell cycle arrest and/or apoptosis (Sewing et al., 1997; Woods et al., 1997; Lundberg et al., 2000; Murphy and Blenis, 2006) , MKP-2 might be required for orchestrating the strength and duration of MAPK signaling to potentiate tumor growth and survival. As observed for endogenous RET activation in the presence of its ligand GDNF and its coreceptor GFRa1 (Supplementary Figure S1) , transient, but not constitutive, expression of MKP-2 could be essential for regulated proliferation in physiological conditions.
Previous studies have reported that the expression of MKP-2 is induced through p53 or E2F-1 transcription factors following oxidative stress (Shen et al., 2006; Wang et al., 2007) . In this context, exogenous overexpression of MKP-2 suppresses the phosphorylation of MAPKs and elevates cellular apoptotic response. We also examined whether the depletion of MKP-2 influences apoptosis of MKK-f cells by oxidative stress or cisplatin, an anticancer drug. However, no significant difference in apoptosis was observed between MKP-2-depleted and control cells (data not shown). The discrepancies between previous reports and our present data may be due to differences in cellular sensitivity against oxidative stress and anticancer reagents. Elucidation of the fundamental principles that determine how the induction and/or activation of MKP-2 results in distinct biological outcomes requires further investigation.
In spite of the remarkable success of MKP-2 knockdown, there is little, if any, effect on the dephosphorylation of the MAPKs in MKK-f cells, which may be accounted for by compensation mechanisms or suggests that the function and substrate specificity of MKP-2 may be much more complicated than previously described. An insight gained from this study is the involvement of MKP-2 in the regulation of cyclin B1 expression and cdc2 kinase activity, both of which are required for G2/M progression of the cell cycle (Norbury and Nurse, 1992; Pines, 1999; Porter and Donoghue, 2003) . Increasing evidence indicates that deregulation and overexpression of cyclin B1 is involved in neoplastic transformation in many tumor types (Soria et al., 2000; Hassan et al., 2002; Yuan et al., 2006) . Constitutive activation of cyclin B1 and associated cdc2 kinase can override the G2 DNA damage checkpoint, which leads to an accumulation of genomic defect found in malignant tumors (Kao et al., 1997; Taylor et al., 1999; Park et al., 2000) . Recent reports that forced RNAi-mediated reduction of cyclin B1-induced continuous apoptosis in tumor cells (Yuan et al., 2004 (Yuan et al., , 2006 are in accordance with this observation. Thus, MKP-2-mediated expression of cyclin B1 may be important for The downregulation of cyclin B1 by the depletion of MKP-2 occurs at the transcriptional level and not through the processes of translation or ubiquitinmediated proteolysis (Figure 5d) . A recent study has revealed that the activity of cyclin B1 promoter and its protein levels are upregulated by oncogenic Ras (Santana et al., 2002) . Ras is also a central mediator of oncogenic signals from RET-MEN2A and RET-MEN2B (Takahashi, 2001; Asai et al., 2006) , raising the possibility that MKP-2 may be involved in Ras-mediated regulation of cyclin B1 expression. Much work is required to elucidate the mechanisms of how MKP-2 regulates cyclin B1 expression.
The immunohistochemical studies revealed that both MKP-2 and cyclin B1 are highly expressed in human MTCs. In contrast, MKP-2 expression was low or undetectable in normal thyroid follicular and parafollicular C cells. These findings suggest an in vivo role of MKP-2 in MTC development. Thus, its downregulation might become a strategy for antitumor intervention for MEN2 patients.
Materials and methods

RET-MEN2A transgenic mice and cDNA microarray analyses
The generation of RET-MEN2A transgenic mice has been described in detail (Kawai et al., 2000) . Total RNA was isolated from freshly dissected salivary, thyroid and mammary tumors from RET-MEN2A transgenic mice and normal Total cell lysates harvested at the indicated time points were subjected to western blot analysis with the indicated antibodies. (f) Control and MKP-2-depleted MKK-f cells were immunostained with anti-lamin A/C antibodies to visualize microtubules and nuclear envelope, respectively. The cells were also stained with the DNA dye DAPI (4 0 ,6-diamino-2-phenylindole). Appearance of cyclin B1 on the spindle poles (arrowheads) at prometaphase was decreased in MKP-2-depleted MKK-f cells compared with control cells. Arrows indicate nuclear envelope identified by lamin A/C staining.
Roles of MKP-2 in RET-MEN2A-induced tumorigenesis T Hasegawa et al tissues from wild-type mice. The messenger RNA (mRNA) was examined by differential hybridization of cDNA microarray slides ('Intelligene' Mouse CHIP Set I; Takara, Shiga, Japan) as previously described (Kawai et al., 2003) . The array was scanned with a Gene Pix 4000A (Amersham, Arlington Heights, IL, USA) and individual spots were quantified using Gene Pix Pro3.0 (Amersham). The background-corrected fluorescence intensity values from each experiment were logtransformed (base 2). Genes were classified as upregulated in the tumors when a comparison with normal tissue expression produced a ratio with an absolute value >2.00.
Quantitative and semiquantitative RT-PCR Total RNA was isolated from carcinoma samples and normal tissues, and cDNA was synthesized following standard procedures. Primers and probes for each cDNA were designed using Primer Express 1.5 software (Applied Biosystems, Foster City, CA, USA). All of the real-time quantitative RT-PCR reactions were performed using the TaqMan PCR Core Reagents Kit and the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Amplification of 18S rRNA was used as the normalization control.
For semiquantitative analyses of MKP-2, cyclin and CDK transcripts, total RNA from MKK-f cells was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA transcripts were then generated using Superscript II (Invitrogen, San Diego, CA, USA). RT-PCR was performed with primers specific to mouse MKP-2 (sense, 
Cell culture
The MKK-f cell line was established from a mammary tumor developed in a RET-MEN2A transgenic mouse (Kawai et al., 2003) . MKK-f cells were maintained at 37 1C in a humidified atmosphere of 5% CO 2 and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 8% fetal bovine serum (FBS). HEK293, COS7 and MEF3T3 Tet-off cells were grown in DMEM supplemented with 8% calf serum.
Antibodies
Mouse anti-MKP-2 monoclonal antibody was purchased from BD Transduction Laboratories (Lexington, KY, USA 
Plasmid construction
Active mutants of MAPKK (pSRa-DSESE-MAPKK) and MKK6 (pcDNA3.1-MKK6-EE) were the generous gift from Dr Y Gotoh (Tokyo University, Tokyo, Japan). Human fulllength MKP-2 cDNA was isolated by PCR from a cDNA library prepared using RNA of TGW neuroblastoma cells. A catalytically inactive mutant of MKP-2 (C280S) (Cadalbert et al., 2005) was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. The cDNAs were subcloned into the pEF1-myc vector (Invitrogen) and used for experiments.
Tet-off system MEF3T3 Tet-off cells (Clontech, Palo Alto, CA, USA) were grown in DMEM supplemented with 10% Tet-off systemapproved FBS (Clontech) containing 50 IU/ml penicillin, 50 mg/ml streptomycin, 2 mmol/l L-glutamine and 100 mg/ml G418 (Roche Diagnostics, Mannheim, Germany), and maintained at 37 1C under a 5% CO 2 atmosphere. The MEF3T3 Tet-off cells grown in 60-mm tissue culture dishes were cotransfected with 10 mg of pTRE/RET-MEN2A or pTRE/RET-MEN2B plasmid and 0.5 mg of pTK-Hygr plasmid (Clontech) using Lipofectamine 2000 (Invitrogen) as described previously (Watanabe et al., 2002) . The cells were detached with trypsin 3 days after transfection and plated in the presence of doxycycline hydrochloride (0.01-1 mg/ml) and hygromycin B (200 mg/ml).The resulting hygromycin-resistant colonies were expanded and maintained in media supplemented with 100 mg/ ml of G418, 100 mg/ml of hygromycin and 200 ng/ml of doxycycline. Expression of the RET-MEN2A and RET-MEN2B proteins was induced by culturing the cells in the absence of doxycycline for 24 or 48 h.
RNA interference
The siRNA-mediated knock down of MKP-2 protein expression was performed using a previously described method Uchida et al., 2006) . The 21-nt synthetic duplexes were purchased from B-Bridge International Inc.
(San Jose, CA, USA). The targeted sequence that effectively silenced mouse MKP-2 expression was 5 0 -CAATCAAGCTT GAAAGTTA-3 0 (sense sequence). MKK-f cells were transfected with either the MKP-2-specific siRNA or 21-nt control siRNA (Qiagen) using Lipofectamine 2000 according to the manufacturer's protocol.
For shRNA-mediated knock down of mouse MKP-2, a set of single-stranded oligonucleotides encoding the MKP-2 target shRNA and its complement was synthesized as follows (only the sense sequence is shown): 5 0 -CCAAGAAATTCTTGTTA CA-3 0 (nt 2347-2365 of mouse MKP-2 cDNA). The oligonucleotide pair was annealed and inserted into the pNAMA retroviral shRNA expression vector (Shirane et al., 2004) . GP293 packaging cells were transfected with 24 mg of control or MKP-2 shRNA-containing pNAMA vectors, 2 mg of pVSVG and 60 ml of Lipofectamine 2000 reagent in 100-mm cell culture dishes in Opti-MEM medium (Invitrogen) without FBS and antibiotics. The medium was replaced 24 h later, and retroviral supernatants were harvested 48 h post-transfection. MKK-f cells (1 Â 10 5 ) were mixed with 3 ml of virus-containing supernatant and seeded in 100-mm cell culture dishes. The supernatant was replaced after a 24-h incubation. Clones in which the expression of MKP-2 was effectively suppressed were selected and used for further study.
Immunohistochemistry
Human MTC tissues were obtained from eight patients who underwent operations at Nagoya University Hospital. Sections were incubated with the anti-MKP-2 and anti-cyclin B1 antibodies overnight at 4 1C. After washing with PBS, they were treated with the secondary antibody, dextran peroxidaseconjugated goat anti-rabbit antibody (Envision System; Dako), and diaminobenzidine was used to visualize immune complexes at room temperature. For immunofluorescent staining, sections were stained with anti-MKP-2 and anti-calcitonin antibodies, followed by Alexa488 or 594-conjugated secondary antibodies. Fluorescence was examined using a confocal laser-scanning microscope (Fluoview FV500; Olympus, Tokyo, Japan).
Western blot analyses
Cells were lysed in SDS sample buffer (20 mM Tris-HCl, pH 6.8; 2 mM EDTA; 2% SDS; 10% sucrose; 20 mg/ml bromophenol blue and 80 mM dithiothreitol). The lysates were ultrasonicated, boiled for 4 min and subjected to SDSpolyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were blocked in 5% albumin in PBS containing 0.05% Tween-20 and probed with the primary antibodies. After washing, they were incubated with the secondary antibodies for 1 h before specific binding was detected by the Enhanced Chemiluminescence System (Amersham).
Cell proliferation assays MKK-f cells were cultured overnight in triplicate (10 3 cells per well in 96-well plates) in DMEM containing 8% FBS. Cell proliferation was measured using WST-1 assays (Roche Applied Science, Indianapolis, IN, USA). The WST-1 reagent (10 ml) was added to 100 ml of cell suspension and incubated for 4 h. The enzyme-linked immunosorbent assay reader was set at a wavelength of 450 nm with a reference wavelength of 620 nm. Data are presented as means ± s.d. for each triplicate sample.
Flow cytometry
Cell cycle profiles were analysed by staining intracellular DNA with propidium iodide, followed by flow cytometry using a Roles of MKP-2 in RET-MEN2A-induced tumorigenesis T Hasegawa et al FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) (Fukuda et al., 2005) .
Tumor growth assay in nude mice
Tumor cells (1 Â 10 6 ) were subcutaneously injected into 7-week-old female nude mice. Over a period of 4 weeks, nude mice were kept in sterilized, filtered cages in a 12-h light-dark cycle under standardized environmental conditions throughout the experiments. The Animal Care and Use Committee of Nagoya University Graduate School of Medicine approved this study.
Data analysis
Data are presented as means±s.d. Statistical significance was evaluated by Student's t-test.
